| 581 | 10 | 38 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：评价华蟾素注射液治疗肝癌的临床有效性及安全性。方法：计算机检索Pubmed数据库、Embase数据库、Cochrane Library数据库、中国知网（CNKI）、万方数据库（Wan Fang）、维普数据库（VIP）、中国生物医学文献服务系统（Sino Med）检索有关华蟾素注射液联合西医治疗原发性肝癌的随机对照实验，检索时间均为建库至2021年6月4日。由2位独立的研究员分别按照纳入标准对文章进行系统筛选、文献纳入、质量评估，采用Rev Man 5.4软件对数据进行Meta分析。结果：共纳入30项研究，总计2 355例患者。华蟾素注射液联合西医治疗相比于常规西医治疗临床有效率更高[RR=1.16,95%CI=(1.11,1.22),P<0.000 01]，能够有效减小瘤体大小[RR=1.33,95%CI=(1.17,1.51),P<0.000 01]、延长患者生存时间[RR=1.41,95%CI=(1.31,1.52),P<0.000 01]、提高生活质量[RR=1.37,95%CI=(1.19,1.57),P<0.00001]、改善患者肝功能[RR=-14.52,95%CI=（-16.15，-12.88）,P<0.000 01]，减轻骨髓抑制[RR=0.44,95%CI=(0.31,0.62),P<0.000 01]等不良反应[RR=0.94,95%CI=(0.85,1.42),P=0.25]的发生。结论：华蟾素注射液联合西医疗法可有效改善原发性肝癌的临床症状，且安全性好。但纳入文献的方法学质量较低，影响结局的客观性，尚需要更加全面的多样本、多中心、随机双盲对照实验进行验证。
Abstract：Objective: To evaluate the clinical efficacy and safety of cinobufagin injection in the treatment of liver cancer.Methods: Pub Med database, Embase database and Cochrane Library database, CNKI, Wanfang database, VIP database and Sinomed database were used to search for the randomized controlled trials of cinobufagin injection combined with Western medicine in the treatment of primary liver cancer. The retrieval time was from the establishment to December 15, 2020. Two independent researchers conducted systematic screening, literature inclusion and quality assessment of the articles according to the inclusion criteria, respectively. Meta-analysis of the data was performed using Rev Man 5.4 software. Results: A total of 30 studies with a total of 2 355 patients were included. Compared with conventional western medicine treatment, the clinical effective rate of Hububutin injection combined with western medicine was significantly higher [RR=1.16,95%CI=(1.11,1.22),P<0.000 01]. It could effectively reduce the tumor size [RR=1.33,95%CI=(1.17,1.51),P<0.000 01], prolong the survival time of patients [RR=1.41,95%CI=(1.31,1.52),P<0.000 01], improve the quality of life [RR=1.37,95%CI=(1.19,1.57),P<0.000 01], improve the liver function of patients [RR=-14.52,95%CI=（-16.15,-12.88）,P<0.000 01], and reduce the occurrence of adverse reactions [RR=0.94,95%CI=(0.85,1.42),P=0.25] such as bone marrow suppression [RR=0.44,95%CI=(0.31,0.62),P<0.000 01]. Conclusion: Cinobufagin injection combined with western medicine therapy can effectively improve the clinical symptoms of primary liver cancer, and the safety is good. However, the methodological quality of the included literature is low, which affects the objectivity of the outcome, and it still needs to be verified by multi-sample, multi-center, randomized double-blind controlled trial.
1 Anwanwan D,Singh SK,Singh S,et al.Challenges in liver cancer and possible treatment approaches[J].Biochim Biophys Acta Rev Cancer,2020,1873(1):188314.
2 Liu Z,Suo C,Mao X,et al.Global incidence trends in primary liver cancer by age at diagnosis,sex,region,and etiology,1990-2017[J].Cancer,2020,126(10):2267-2278.
3 Petrowsky H,Fritsch R,Guckenberger M,et al.Modern therapeutic approaches for the treatment of malignant liver tumours[J].Nat Rev Gastroenterol Hepatol,2020,17(12):755-772.
4 Kong WS,Shen FX,Xie RF,et al.Bufothionine induces autophagy in H22 hepatoma-bearing mice by inhibiting JAK2/STAT3 pathway,a possible anti-cancer mechanism of cinobufacini[J].J Ethnopharmacol,2021,270:113848.
5 Zhao L,Fu L,Xu Z,et al.The anticancer effects of cinobufagin on hepatocellular carcinoma Huh-7 cells are associated with activation of the p73 signaling pathway[J].Mol Med Rep,2019,19(5):4119-4128.
6 Turner T,Green S,Tovey D,et al.Producing Cochrane systematic reviews-A qualitative study of current approaches and opportunities for innovation and improvement[J].Syst Rev,2017,6(1):147.
7黄小鹰，许小林，陈海萍，等.华蟾素联合乌苯美司治疗中晚期原发性肝癌30例疗效观察[J].药品评价，2020,17(16):62-64.
8王黎，刘怡君.华蟾素注射液在原发性肝癌患者介入治疗中辅助作用[J].中华实用诊断与治疗杂志，2020,34(8):844-847.
9孙德喜，王彩霞.华蟾素注射液联合TACE及微波消融治疗HBV感染的中晚期肝癌的近期疗效分析[J].系统医学，2019,4(22):133-135.
10李佳，曾宝珠，孙志刚.动脉置管灌注华蟾素注射液联合TACE术治疗原发性肝癌的临床研究[J].湖北中医杂志，2019,41(1):12-15.
11田思源，徐爱兵，黄洪华，等.华蟾素联合FOLFOX4方案治疗中晚期肝癌60例疗效观察[J].中国处方药，2016,14(11):72-73.
12贾金莹.华蟾素联合经肝动脉化疗栓塞治疗原发性肝细胞癌的临床效果[J].中国当代医药，2016,23(8):52-54,57.
13邓振云，段浩博.华蟾素联合TACE治疗原发性肝癌临床观察[J].天津中医药，2015,32(5):275-278.
14赵直光，唐中权.华蟾素注射液治疗肝癌的临床应用价值[J].内蒙古医学杂志，2015,47(2):172-175.
15杨光辉，薛涛，李萍，等.华蟾素注射液对原发性肝癌患者血清前白蛋白及血管内皮生长因子的影响[J].中华中医药学刊，2014,32(5):1086-1088.
16龙德，赵永心，卢慕舜，等.华蟾素治疗中晚期原发性肝癌HBV-DNA高表达患者的近期疗效[J].广州中医药大学学报，2014,31(1):35-39.
17苏英，杨健全，郭长青.华蟾素注射液联合经导管肝动脉化疗栓塞治疗晚期原发性肝癌[J].肿瘤基础与临床，2013,26(3):245-246.
18余建国.华蟾素注射液联合肝动脉栓塞化疗治疗原发性肝癌临床观察[J].现代消化及介入诊疗，2013,18(1):32-33.
19何胜利，刘鲁明，孙贤俊，等.华蟾素注射液联合含奥沙利铂方案肝动脉化疗栓塞治疗肝癌临床疗效观察[J].中华临床医师杂志（电子版），2012,6(14):3880-3883.
20冯献明，付方现，韩文清，等.FOLFOX4方案联合华蟾素治疗中晚期肝癌52例临床观察[J].中国社区医师（医学专业），2012,14(17):79.
21张小玉，呼永河，唐春果，等.华蟾素辅助立体定向体部伽玛刀治疗原发性肝癌的临床研究[J].中华临床医师杂志（电子版），2011,5(7):1901-1905.
22付志龙，曲卓慧，王焱.华蟾素联合介入疗法治疗中晚期肝癌的临床研究[J].中国实用医药，2010,5(34):107-108.
23周晓斌.华蟾素注射液治疗原发性肝癌临床观察58例[J].中国实用医药，2010,5(23):6-7.
24刘永强，余志红，邵志华，等.静脉注射华蟾素联合TACE术治疗肝癌的临床观察[J].中国农村卫生事业管理，2010,30(5):402-404.
25薛骞，卢丽琴，袁国荣，等.华蟾素联合TACE术治疗中晚期肝癌患者32例临床研究[J].江苏中医药，2010,42(2):22-24.
26马英杰，马玉平.华蟾素注射液治疗中晚期原发性肝癌临床疗效观察[J].辽宁中医药大学学报，2010,12(1):124-125.
27刘小红，傅浩，祝强华，等.华蟾素注射液联合TACE治疗肝癌的临床研究[J].中国现代药物应用，2009,3(23):134-135.
28黄智芬，黎汉忠，陈强松，等.华蟾素注射液结合西药治疗晚期原发性肝癌对生活质量及免疫功能的影响[J].云南中医学院学报，2009,32(4):47-49.
29沈建军.华蟾素介入栓塞联合静脉注射对原发性肝癌的临床疗效[J].临床肝胆病杂志，2009,25(3):207-209.
30倪秉强，张志红，陈日新，等.华蟾素联合支持疗法在晚期肝癌治疗中的使用价值[J].内科，2009,4(2):197-199.
31梁永，龙健中，刘航，等.华蟾素和干扰素联合肝动脉化疗栓塞术治疗原发性肝细胞癌的研究[J].现代中西医结合杂志，2008,(11):1628-1630.
32李琦，孙保木，彭永海，等.华蟾素联合肝动脉介入化疗栓塞治疗肝癌的临床研究[J].上海中医药大学学报，2008,(2):32-34.
33李文华，尹军平，王兴卉，等.联合华蟾素栓塞化疗中晚期肝癌的疗效观察[J].世界临床药物，2006,(5):310-312.
34周建生，陆浩，吴晓东，等.华蟾素联合肝动脉化学药物栓塞治疗原发性肝癌疗效观察[J].中国基层医药，2006,(4):571-572.
35陈喆，翟笑枫，苏永华，等.华蟾素注射液治疗中晚期原发性肝癌临床疗效观察[J].中西医结合学报，2003,(3):184-186.
36孙中杰，潘承恩，王国俊.华蟾素配合TACE治疗肝癌的临床观察[J].肿瘤防治研究，2002,(1):67-68.
37 Li L,Wang H.Heterogeneity of liver cancer and personalized therapy[J].Cancer Lett,2016,379(2):191-197.
38吴宏磊，陈进宝，徐可，等.华蟾素抗肿瘤作用及其机制研究进展[J].中国临床药理学杂志，2021,37(2):192-196.
39 Cao YT,Cui KK,Wu JH,et al.Correlative study of bufogenin constituents in venom of Bufo bufo gargarizans[J].Zhongguo Zhong Yao Za Zhi,2019,44(9):1850-1856.
40 Zhan X,Wu H,Wu H,ea tl.Metabolites from Bufo gargarizans (Cantor,1842):A review of traditional uses,pharmacological activity,toxicity and quality control[J].J Ethnopharmacol,2020,246:112178.
41 Pan Z,Zhang X,Yu P,et al.Cinobufagin induces cell cycle arrest at the G2/M phase and promotes apoptosis in malignant melanoma cells[J].Front Oncol,2019,9:853.
42 Cheng CS,Wang J,Chen J,et al.New therapeutic aspects of steroidal cardiac glycosides:The anticancer properties of Huachansu and its main active constituent Bufalin[J].Cancer Cell Int,2019,19:92.
43 Bhide A,Shah PS,Acharya G.A simplified guide to randomized controlled trials[J].Acta Obstet Gynecol Scand,2018,97(4):380-387.
基本信息:
DOI：10.13210/j.cnki.jhmu.20210713.001
中图分类号:R735.7
引用信息:
[1]任思思,范妤,郭东艳,等.华蟾素注射液联合西医疗法治疗肝癌有效性与安全性的系统评价Meta分析[J].海南医学院学报,2023,29(06):452-462.DOI:10.13210/j.cnki.jhmu.20210713.001.
基金信息:
陕西中医药大学创新团队项目（2019-YL14,2019-YL11）~~
2021-07-13
2021-07-13
2021-07-13